Crescita Therapeutics swings to Q2 profit as revenue rises over 50%

Crescita Therapeutics

06/08/2025 13:10

Overview

Crescita Q2 revenue rises 52.5% yr/yr, driven by manufacturing and Croma payment

Net income reaches C$798k, reversing a loss from prior year

Adjusted EBITDA improves significantly, reflecting operational efficiencies

Outlook

Crescita exploring partnerships for Pliaglis in European markets

Crescita regained Pliaglis rights in several territories after Croma termination

Company actively seeking new partners for Pliaglis commercialization

Result Drivers

MANUFACTURING VOLUMES - Revenue increase driven by ramp-up of production volumes with new customer in Manufacturing segment

TERMINATION PAYMENT - CAD 900,000 added to revenue from mutual termination agreement with Croma

SKINCARE GROWTH - Skincare segment sales rose due to Aquafolia acquisition and higher export sales

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
C$6.23 mln
Q2 Adjusted EBITDA
C$964,000
Q2 Gross Margin
61.4%
Q2 Operating Expenses
C$3.24 mln
Q2 Operating Income
C$583,000


Press Release: ID:nBw7zNX2Na

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)